BioVie has completed its previously announced best efforts public offering, raising approximately $3 million in gross proceeds. The offering included 1,360,800 shares of common stock, pre-funded warrants to purchase 600,000 shares, and warrants to purchase up to 1,960,800 shares at a combined price of $1.53 per share or pre-funded warrant. The common warrants are immediately exercisable for five years at $1.53 per share.Following the offering's completion, the company adjusted the exercise price of Acuitas Group Holdings' warrant from $10.00 to $1.53, effective September 25, 2024, in accordance with the warrant's terms. The net proceeds, after deducting approximately $210,000 in placement agent fees and offering expenses, will be used primarily for working capital and general corporate purposes.ThinkEquity served as the sole placement agent for the offering, which was conducted under the company's shelf registration statement. The securities were offered through a prospectus supplement and accompanying prospectus filed with the SEC.

BioVie has completed its previously announced best efforts public offering, raising approximately $3 million in gross proceeds. The offering included 1,360,800 shares of common stock, pre-funded warrants to purchase 600,000 shares, and warrants to purchase up to 1,960,800 shares at a combined price of $1.53 per share or pre-funded warrant. The common warrants are immediately exercisable for five years at $1.53 per share.Following the offering's completion, the company adjusted the exercise price of Acuitas Group Holdings' warrant from $10.00 to $1.53, effective September 25, 2024, in accordance with the warrant's terms. The net proceeds, after deducting approximately $210,000 in placement agent fees and offering expenses, will be used primarily for working capital and general corporate purposes.ThinkEquity served as the sole placement agent for the offering, which was conducted under the company's shelf registration statement. The securities were offered through a prospectus supplement and accompanying prospectus filed with the SEC.